help button home button Am J Pathol ASIP MEMBERSHIP
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shaaban, A. M.
Right arrow Articles by Foster, C. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shaaban, A. M.
Right arrow Articles by Foster, C. S.
(American Journal of Pathology. 2002;160:597-604.)
© 2002 American Society for Investigative Pathology


Regular Articles

Breast Cancer Risk in Usual Ductal Hyperplasia Is Defined by Estrogen Receptor-{alpha} and Ki-67 Expression

Abeer M. Shaaban*, John P. Sloane*, Christopher R. West{dagger} and Christopher S. Foster*

From the Departments of Cellular and MolecularPathology*
and PublicHealth,{dagger}
University of Liverpool, Liverpool,United Kingdom

The hypothetical multistep model for breast carcinogenesis indicates that invasive carcinoma arises via a series of intermediate hyperplastic lesions through various grades of atypia to in situ and invasive carcinoma. Non-atypical hyperplasia [hyperplasia of usual type (HUT)] is a nonobligate precursor of breast cancer. Although its further morphological subclassification is unlikely, refining is more likely to depend on defining biological markers of risk. Having assembled a cohort of benign proliferative breast lesions of known outcome, we studied the expression of estrogen receptor-{alpha} (ER-{alpha}) and Ki-67 using morphometric image analysis as well as dual-labeled immunofluorescence in HUT foci and in surrounding normal lobules of 25 patients that progressed to breast cancer and 19 controls. Those patients that progressed to breast cancer (cases) showed significantly higher ER-{alpha} [median, 57.00% of cells within individual HUT foci; interquartile range (IQ), 33.48 to 67.78] and Ki-67 (median, 3.82%; IQ, 0.85 to 11.28) expression in their HUT foci compared with controls (ER-{alpha} median, 30.27%; IQ, 19.75 to 52.50 and Ki-67 median, 0.77%; IQ, 0.0458 to 1.72, P = 0.008 and <0.001). No significant difference in expression of dual-stained cells was found between cases and controls. Although normal lobules from cases showed higher ER-{alpha} expression compared with controls, this was not statistically significant. Our data point to a previously undescribed hormone-dependent pathway in this particular group of breast neoplasms and suggest the possibility of selective hormonal therapy to suppress the proliferative potential of these benign but high-risk breast lesions. The findings of this study might have important implications for improving breast cancer screening and management strategies.





This article has been cited by other articles:


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
D. M. Euhus, D. Bu, S. Milchgrub, X.-J. Xie, A. Bian, A. M. Leitch, and C. M. Lewis
DNA Methylation in Benign Breast Epithelium in Relation to Age and Breast Cancer Risk
Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1051 - 1059.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
S. N. Sundar, V. Kerekatte, C. N. Equinozio, V. B. Doan, L. F. Bjeldanes, and G. L. Firestone
Indole-3-Carbinol Selectively Uncouples Expression and Activity of Estrogen Receptor Subtypes in Human Breast Cancer Cells
Mol. Endocrinol., December 1, 2006; 20(12): 3070 - 3082.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
C. J. Fabian and B. F. Kimler
Mammographic Density: Use in Risk Assessment and as a Biomarker in Prevention Trials
J. Nutr., October 1, 2006; 136(10): 2705S - 2708S.
[Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
M. Cazzaniga, G. Severi, C. Casadio, L. Chiapparini, U. Veronesi, and A. Decensi
Atypia and ki-67 expression from ductal lavage in women at different risk for breast cancer.
Cancer Epidemiol. Biomarkers Prev., July 1, 2006; 15(7): 1311 - 1315.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
D. Bhandare, R. Nayar, M. Bryk, N. Hou, R. Cohn, N. Golewale, N. P. Parker, R. T. Chatterton, A. Rademaker, and S. A. Khan
Endocrine Biomarkers in Ductal Lavage Samples from Women at High Risk for Breast Cancer
Cancer Epidemiol. Biomarkers Prev., November 1, 2005; 14(11): 2620 - 2627.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
G. Arpino, R. Laucirica, and R. M. Elledge
Premalignant and In Situ Breast Disease: Biology and Clinical Implications
Ann Intern Med, September 20, 2005; 143(6): 446 - 457.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
S A Khan, D Bhandare, and R T Chatterton Jr
The local hormonal environment and related biomarkers in the normal breast
Endocr. Relat. Cancer, September 1, 2005; 12(3): 497 - 510.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
D. Bhandare, S. A. Khan, C. J. Fabian, and Q. J. Khan
Ki-67 Expression in Benign Breast Ductal Cells Obtained by Random Periareolar Fine Needle Aspiration
Cancer Epidemiol. Biomarkers Prev., September 1, 2005; 14(9): 2278 - 2279.
[Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
Q. J. Khan, B. F. Kimler, J. Clark, T. Metheny, C. M. Zalles, and C. J. Fabian
Ki-67 Expression in Benign Breast Ductal Cells Obtained by Random Periareolar Fine Needle Aspiration
Cancer Epidemiol. Biomarkers Prev., April 1, 2005; 14(4): 786 - 789.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
K. Muller-Decker, I. Berger, K. Ackermann, V. Ehemann, S. Zoubova, S. Aulmann, W. Pyerin, and G. Furstenberger
Cystic Duct Dilatations and Proliferative Epithelial Lesions in Mouse Mammary Glands upon Keratin 5 Promoter-Driven Overexpression of Cyclooxygenase-2
Am. J. Pathol., February 1, 2005; 166(2): 575 - 584.
[Abstract] [Full Text] [PDF]


Home page
J Mol EndocrinolHome page
M P A Davies, P A O'Neill, H Innes, D R Sibson, W Prime, C Holcombe, and C S Foster
Correlation of mRNA for oestrogen receptor beta splice variants ER{beta}1, ER{beta}2/ER{beta}cx and ER{beta}5 with outcome in endocrine-treated breast cancer
J. Mol. Endocrinol., December 1, 2004; 33(3): 773 - 782.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. J. Fabian, B. F. Kimler, J. Anderson, O. W. Tawfik, M. S. Mayo, W. E. Burak Jr., J. A. O'Shaughnessy, K. S. Albain, D. M. Hyams, G. T. Budd, et al.
Breast Cancer Chemoprevention Phase I Evaluation of Biomarker Modulation by Arzoxifene, a Third Generation Selective Estrogen Receptor Modulator
Clin. Cancer Res., August 15, 2004; 10(16): 5403 - 5417.
[Abstract] [Full Text] [PDF]


Home page
Jpn J Clin OncolHome page
V. Papantoniou, J. Koutsikos, M. Sotiropoulou, E. Mainta, D. Lazaris, S. Tsiouris, and C. Zerva
Scintimammographic Findings of Phyllodes Tumor of the Breast in a Double-phase Study with Tc-99m (V)DMSA and Tc-99m MIBI: a Case Report
Jpn. J. Clin. Oncol., July 1, 2004; 34(7): 429 - 431.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. J. Fabian, B. F. Kimler, D. A. Brady, M. S. Mayo, C. H. J. Chang, J. A. Ferraro, C. M. Zalles, A. L. Stanton, S. Masood, W. E. Grizzle, et al.
A Phase II Breast Cancer Chemoprevention Trial of Oral {alpha}-Difluoromethylornithine: Breast Tissue, Imaging, and Serum and Urine Biomarkers
Clin. Cancer Res., October 1, 2002; 8(10): 3105 - 3117.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Society for Investigative Pathology.